SGMT

Sagimet Biosciences Inc

9.92

Oct 30 • 3:59 PM ET -0.51 (-4.89%)

9.92

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: MDGL IVA ALT VKTX GALT SLGL KLRA LPCN NVO GSK

| Held by: VTI IWM XBI VXF IBB IWO VTWO DFAS IWC DWAS

Scroll to Statements

Index	RUT
Market Cap	697.78M
Enterprise Value	459.59M
Income	-47.08M
Sales	0.00M
Book/sh	4.15
Cash/sh	3.41
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	16
IPO	Jul 14, 2023

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.39
P/C	2.91
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	44.94
Current Ratio	44.94
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-1.28
EPS next Y	-1.34
EPS next Q	-0.26
EPS this Y	28.71%
EPS next Y	-19.27%
EPS next 5Y	-0.08%
EPS past 3/5Y	-3.41% -24.29%
Sales past 3/5Y	- -
EPS Y/Y TTM	30.54%
Sales Y/Y TTM	-
EPS Q/Q	18.57%
Sales Q/Q	-
Earnings	Aug 11 BMO
EPS/Sales Surpr.	-3.59% -

Insider Own	7.47%
Insider Trans	-8.12%
Inst Own	74.08%
Inst Trans	112.28%
ROA	-23.49%
ROE	-24.37%
ROIC	-18.25%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	7.69%
SMA50	-0.13%
SMA200	32.33%
Trades

Shs Outstand	70.91M
Shs Float	65.61M
Short Float	17.57%
Short Ratio	8.63
Short Interest	11.53M
52W High	11.45 -13.35%
52W Low	4.50 120.44%
Volatility	6.26% 6.58%
ATR (14)	0.64
RSI (14)	53.18
Beta	3.48
Rel Volume	0.74
Avg Volume	1.34M
Volume	989,160

Perf Week	3.55%
Perf Month	5.87%
Perf Quarter	38.74%
Perf Half Y	30.35%
Perf YTD	67.57%
Perf Year	21.87%
Perf 3Y	171.04%
Perf 5Y	-
Perf 10Y	-
Recom	1.36
Target Price	27.92
Prev Close	10.43
Price	9.92
Change %	-4.89%

Consensus

Strong Buy

Avg. Price Target

$27.92

Implied Upside

+181.5%

Analysts14incl. previous ratings

Rating Distribution13 Buy · 0 Hold · 1 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 24, 2026	Resumed	GGoldman	Sell	$7	-29.4%
Sep 09, 2026	Upgrade	BBarclays	Equal Weight → Overweight	$18	+81.5%
Sep 09, 2026	Initiated	CCantor Fitzgerald	Overweight
Mar 26, 2026	Initiated	RRodman & Renshaw	Buy	$28	+182.3%
Feb 03, 2026	Initiated	GGuggenheim	Buy	$27	+172.2%
Jan 28, 2026	Initiated	BBarclays	Equal Weight	$8	-19.4%
Aug 11, 2025	Initiated	WWedbush	Outperform	$28	+182.3%
Aug 07, 2025	Resumed	HH.C. Wainwright	Buy	$29	+192.3%
Jul 24, 2025	Initiated	CCanaccord Genuity	Buy	$28	+182.3%
Dec 06, 2024	Initiated	OOppenheimer	Outperform	$30	+202.4%
Nov 12, 2024	Initiated	UUBS	Buy	$12	+21.0%
Jun 28, 2024	Downgrade	GGoldman	Buy → Neutral	$23 → $6	-39.5%
May 02, 2024	Initiated	HH.C. Wainwright	Buy	$32	+222.6%
Mar 25, 2024	Initiated	LLeerink Partners	Outperform	$26	+162.1%
Aug 08, 2023	Initiated	TTD Cowen	Outperform
Aug 08, 2023	Initiated	PPiper Sandler	Overweight	$67	+575.4%
Aug 08, 2023	Initiated	JJMP Securities	Mkt Outperform	$30	+202.4%
Aug 08, 2023	Initiated	GGoldman	Buy	$33	+232.7%

Oct-29-26 07:00AM	Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-22-26 07:00AM	Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne (GlobeNewswire)
Oct-09-26 07:00AM	Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference (GlobeNewswire)
Oct-01-26 04:31PM	Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants (GlobeNewswire) -5.16%
Sep-30-26 09:52AM	Sagimet Biosciences Shares Rise 12% After Denifanstat Phase 3 Acne Trial Data (InvestorsHub) +5.89%
08:17AM	Loading…
08:17AM	Sagimet Raises $115M At Premium To Fund Phase 3 Acne Drug Trial SGMT Stock Surges Pre-Market (Stocktwits)
06:19AM	Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants (GlobeNewswire)
06:00AM	Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026 (GlobeNewswire)
Sep-28-26 07:00AM	Sagimet Biosciences to Host Virtual KOL Event, "Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US" on September 30, 2026 (GlobeNewswire) +7.58%
Sep-02-26 07:00AM	Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-25-26 07:00AM	Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026 (GlobeNewswire)
Aug-17-26 04:28PM	Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-13-26 07:00AM	Sagimet Biosciences Receives FDA "Study May Proceed" Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients (GlobeNewswire)
Aug-11-26 07:30AM	Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates (GlobeNewswire)
Aug-04-26 07:00AM	Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference (GlobeNewswire) +11.75%
07:00AM	Loading…
Jun-29-26 07:00AM	Sagimet Biosciences Joins the Russell 2000 and Russell 3000 Indexes (GlobeNewswire) +10.34%
Jun-22-26 08:49PM	Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.29%
May-27-26 07:00AM	Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH (GlobeNewswire)
May-13-26 07:00AM	Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
May-12-26 07:30AM	Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates (GlobeNewswire)
May-11-26 07:00AM	Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago (GlobeNewswire)
Apr-27-26 11:13AM	Sagimet Biosciences Shares Jump 30% on Acne Trial Expansion Plans (InvestorsHub) +38.57%
10:30AM	BC-Most Active Stocks (Associated Press)
07:15AM	Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock (GlobeNewswire)
07:00AM	Sagimet Biosciences Provides Strategic and Corporate Updates (GlobeNewswire)
Apr-20-26 07:00AM	Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer (GlobeNewswire)
Apr-06-26 07:00AM	Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-11-26 07:30AM	Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates (GlobeNewswire)
Mar-01-26 03:38PM	Sagimet Biosciences Highlights Denifanstat MASH Data, Combo Plans at Oppenheimer Healthcare Conf. (MarketBeat)
Feb-25-26 07:00AM	Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences (GlobeNewswire)
03:06AM	Loading…
Feb-15-26 03:06AM	Sagimet Biosciences Showcases FASN Strategy, MASH Phase II Timeline and Acne Data at Guggenheim Conference (MarketBeat)
Feb-05-26 07:00AM	Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences (GlobeNewswire) -10.53%
Feb-03-26 03:27PM	After Clearing Up Acne, Sagimet Stock Rises (Barrons.com) +5.30%
09:34AM	Adobe downgraded, Palantir upgraded: Wall Street's top analyst calls (The Fly)
Feb-02-26 07:00AM	Sagimet Announces Positive 52-Week Data from License Partner Ascletis' Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne (GlobeNewswire) +9.88%
Jan-08-26 07:00AM	Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference (GlobeNewswire)
Dec-18-25 07:00AM	Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination (GlobeNewswire)
Dec-17-25 07:00AM	Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet's Fixed Dose Combination Program (GlobeNewswire)
Dec-10-25 07:03AM	Sagimet's License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China's National Medical Products Administration (GlobeNewswire)
Dec-09-25 04:05PM	Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-20-25 07:00AM	Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference (GlobeNewswire) -7.39%
Nov-13-25 07:30AM	Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire) -12.24%
Nov-10-25 07:00AM	Sagimet Biosciences Presents Two Denifanstat Posters at AASLD-The Liver Meeting 2025 (GlobeNewswire) +10.77%
Oct-24-25 07:00AM	Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference (GlobeNewswire) +24.69%
Oct-15-25 12:00PM	All You Need to Know About Sagimet Biosciences Inc. (SGMT) Rating Upgrade to Strong Buy (Zacks)
Oct-14-25 07:00AM	Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences (GlobeNewswire)
Oct-07-25 07:00AM	Sagimet Biosciences Announces Upcoming Presentation at AASLD-The Liver Meeting 2025 (GlobeNewswire)
Oct-01-25 07:00AM	Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination (GlobeNewswire)
Sep-24-25 07:00AM	Sagimet Biosciences Announces Upcoming Panel Participation at Fierce Biotech Week (GlobeNewswire) +8.17%
Sep-17-25 07:00AM	Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis (GlobeNewswire)
Sep-16-25 09:35AM	Here's Why Sagimet Biosciences Inc. (SGMT) is Poised for a Turnaround After Losing 15.8% in 4 Weeks (Zacks)
Sep-10-25 07:00AM	Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit (GlobeNewswire)
Aug-26-25 07:00AM	Sagimet Biosciences to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-20-25 12:00PM	Sagimet Biosciences Inc. (SGMT) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:35AM	After Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT) (Zacks)
Aug-13-25 07:30AM	Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire)
Aug-07-25 09:56AM	Eli Lilly downgraded, Lyft upgraded: Wall Street's top analyst calls (The Fly)
Aug-05-25 07:00AM	Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire) +6.04%
Jun-11-25 12:00PM	What Makes Sagimet Biosciences Inc. (SGMT) a Strong Momentum Stock: Buy Now? (Zacks)
Jun-09-25 09:55AM	Wall Street Analysts Predict a 437.05% Upside in Sagimet Biosciences Inc. (SGMT): Here's What You Should Know (Zacks)
07:00AM	Sagimet Biosciences to Host Virtual KOL Event, "A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne" on June 16, 2025 (GlobeNewswire)
Jun-06-25 07:02AM	Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update (BioPharma Dive) +16.32%
Jun-04-25 08:28AM	Sagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Trial In China, Stock Jumps (Benzinga) +12.40%
05:00AM	Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis (GlobeNewswire)
May-22-25 08:00AM	Sagimet Biosciences to Host Virtual KOL Event, "Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)" on May 29, 2025 (GlobeNewswire) +5.90%
May-08-25 06:00AM	Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire)
Apr-23-25 08:00AM	Sagimet Biosciences Announces Upcoming Presentations at EASL Congress 2025 (GlobeNewswire) +8.82%
Mar-12-25 07:30AM	Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
Mar-11-25 08:00AM	Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne (GlobeNewswire)
Feb-25-25 08:25AM	Is Sagimet Biosciences Inc. (SGMT) the Best Get Rich Quick Stock to Invest In? (Insider Monkey)
Feb-22-25 05:24PM	Sagimet Biosciences Inc. (SGMT): Among the Hot Penny Stocks to Buy Now (Insider Monkey)
Feb-19-25 08:00AM	Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium (GlobeNewswire)
Jan-06-25 08:00AM	Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference (GlobeNewswire) +36.42%
Dec-15-24 06:04AM	Oppenheimer Predicts Up to ~580% Jump for These 2 Strong Buy Stocks (TipRanks)
Nov-26-24 08:00AM	Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-18-24 08:00AM	Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting 2024 (GlobeNewswire) -7.82%
Nov-14-24 08:00AM	Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire) -13.95%
Nov-12-24 06:30AM	Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne (PR Newswire)
Nov-07-24 07:30AM	Sagimet Biosciences to Participate in the UBS Global Healthcare Conference (GlobeNewswire)
Oct-29-24 07:00AM	Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024 (GlobeNewswire)
Oct-16-24 07:00AM	Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting 2024 (GlobeNewswire) +6.43%
Oct-11-24 07:00AM	Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology (GlobeNewswire)
Oct-01-24 07:00AM	Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH (GlobeNewswire) +12.64%
12:05AM	Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-12-24 07:30AM	Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit (GlobeNewswire) -9.57%
Sep-04-24 08:00AM	Sagimet Biosciences to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-14-24 08:00AM	Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire) -7.14%
Aug-01-24 08:00AM	Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors (GlobeNewswire)
Jun-10-24 08:00AM	Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat (GlobeNewswire)
Jun-06-24 05:00AM	Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024 (GlobeNewswire)
May-16-24 08:00AM	Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024 (GlobeNewswire)
May-15-24 12:53PM	SGMT Stock Earnings: Sagimet Biosciences Beats EPS for Q1 2024 (InvestorPlace) +5.48%
08:00AM	Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
May-07-24 08:00AM	Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024 (GlobeNewswire)
May-06-24 08:00AM	Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer (GlobeNewswire)
Apr-22-24 08:00AM	Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024 (GlobeNewswire)
Mar-27-24 04:01PM	Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat (GlobeNewswire) +9.56% -5.41%
Mar-25-24 07:00AM	Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors (GlobeNewswire) +15.74%
06:15AM	Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates (GlobeNewswire)
Feb-29-24 08:00AM	Sagimet Biosciences to Participate in Two Upcoming Investor Conferences (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kemble George	Director	Aug 14 '26	Option Exercise	6.36	350,987	2,232,277	413,148	Aug 17 04:05 PM
Kemble George	Director	Aug 14 '26	Sale	10.23	350,987	3,591,580	62,161	Aug 17 04:05 PM
GEORGE KEMBLE	Director	Aug 14 '26	Proposed Sale	9.28	350,987	3,257,159		Aug 14 04:34 PM
Kemble George	Director	Aug 11 '26	Option Exercise	6.36	20,206	128,510	82,367	Aug 12 07:41 PM
Kemble George	Director	Aug 11 '26	Sale	9.95	20,206	201,147	62,161	Aug 12 07:41 PM
GEORGE KEMBLE	Director	Aug 11 '26	Proposed Sale	9.57	20,206	193,371		Aug 11 04:30 PM
Happel David	President & CEO	Jul 20 '26	Sale	7.76	64,051	497,068	741,570	Jul 22 04:05 PM
Rozek Elizabeth	Chief Legal & Admin. Officer	Jul 20 '26	Sale	7.76	10,545	81,832	224,414	Jul 22 04:05 PM
Kemble George	Director	Jul 20 '26	Sale	7.46	18,844	140,529	62,161	Jul 22 04:05 PM
GEORGE KEMBLE	Director	Jul 20 '26	Proposed Sale	7.82	18,844	147,360		Jul 20 04:18 PM
Happel David	President & CEO	Feb 10 '26	Sale	5.36	12,101	64,865	677,621	Feb 12 04:08 PM
Chauche Thierry	Chief Financial Officer	Feb 10 '26	Sale	5.36	1,312	7,033	15,688	Feb 12 04:07 PM
Martins Eduardo Bruno	Chief Medical Officer	Feb 10 '26	Sale	5.36	3,640	19,511	103,296	Feb 12 04:06 PM
Rozek Elizabeth	Chief Legal & Admin. Officer	Feb 10 '26	Sale	5.36	2,622	14,054	190,959	Feb 12 04:05 PM
Kemble George	Executive Chairman	Nov 20 '25	Sale	7.69	37,688	289,979	81,005	Nov 21 06:13 PM
GEORGE KEMBLE	Director	Nov 20 '25	Proposed Sale	7.85	37,688	295,851		Nov 20 04:21 PM

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

CEOMr. David A. Happel

J.D.Ms. Elizabeth Rozek Esq.

Co-FounderMr. Urs Greber Ph.D.

Co-FounderDr. Lucas Pelkmans Ph.D.

CFO & Principal Accounting OfficerMr. Thierry Chauche

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SGMT

Sagimet Biosciences Inc

Upgrade your Finviz experience